a Clinical Study to Evaluate the Safety, Pharmacokinetic Profile and Efficacy of CU-20401 Administered Subcutaneously in the Submental Fat (SMF) Population
Latest Information Update: 12 Dec 2024
At a glance
- Drugs CU-20401 (Primary)
- Indications Subcutaneous fat disorders
- Focus Adverse reactions
- Sponsors Cutia Therapeutics
Most Recent Events
- 04 Sep 2023 Allocation is changed to Non-Randomized.
- 04 Sep 2023 Status changed from recruiting to completed.
- 06 Feb 2023 Planned End Date changed from 30 Dec 2022 to 30 Dec 2024.